Bibliography
- Mack WJ, Selzer RH, Hodis HN, et al. One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Stroke 1993;24:1779-83
- Nikkila EA, Viikinkoski P, Valle M, Frick MH. Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study. Br Med J 1984;289:220-3
- Pritzker LB. Do lipid lowering drugs reduce the risk of coronary heart disease? Crit Rev Clin Lab Sci 1998;35:603-21
- Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005;258:94-114
- Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511
- Offermanns S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol Sci 2006;27:384-90
- Abbott. Press release. Available from: http://www.abbott.com
- Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008;101:625-30
- SmithKline Beecham Corp. WO9856820; 1998
- Glaxo Group, Ltd. WO02084298; 2002
- Wise A, Foord SM, Fraser NJ, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003;278:9869-74
- Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003;9:352-5
- Arena. US20030166148; 2003
- Shen HC, Ding F, Taggart A, et al. Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor. J Med Chem 2007;50:6303-6
- Shen HC, Szymonifka M, Deng Q, et al. Discovery of orally bioavailable and novel urea agonists for the high affinity niacin receptor GPR109A. Bioorg Med Chem Lett 2007;17:6723-8
- Semple G, Skinner PJ, Gharbaoui T, et al. 3-(1H-Tetrazol-5-yl)-1,4,5,6-tetrahydro-cycopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. J Med Chem 2008;51:5101-8
- Lai E, Waters MG, Tata JR, et al. Effect of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. J Clin Lipidol 2008;2:375-83
- Incyte corporation presentation at JP Morgan Healthcare Conference (January 8, 2008;). Available from: http://findarticles.com/p/articles/mi_m0EIN/is_2008_jan_8/ai_n24224669
- Study ID NCT00698789. Available from: www.clinicaltrials.gov
- Semple G, Boatman PD, Richman JG. Recent progress in the discovery of niacin receptor agonists. Curr Opin Drug Discov Dev 2007;10:452-9
- Boatman PD, Richman JG, Semple G. Nicotinic acid receptor agonists. J Med Chem 2008;51:7653-62
- SmithKline Beecham Corp. WO2005016867; 2005
- SmithKline Beecham Corp. WO2005016870; 2005
- SmithKline Beecham Corp. WO2006085113; 2006
- Merck & Co., Inc. WO2006052555; 2006
- Merck & Co., Inc. WO2006057922; 2006
- Merck & Co., Inc. WO2007120575; 2007
- Merck & Co., Inc. WO2007002557; 2007
- Merck & Co., Inc. WO2007092364; 2007
- Tunaru S, Lättig J, Kero J, et al. Characterization of determinants of ligand binding to the nicotinic acid receptor (HM74A/PUMA-G). Mol Pharmacol 2005;68:1271-80
- Deng Q, Frie JL, Marley DM, et al. Molecular modeling aided design of nicotinic acid receptor GPR109A agonists. Bioorg Med Chem Lett 2008;18:4963-7
- Raghavan S, Tria GS, Shen HC, et al. Tetrahydro anthranilic acid as a surrogate for anthranilic acid: application to the discovery of potent niacin receptor agonists. Bioorg Med Chem Lett 2008;18:3163-7